Category Archives: Other

Policy Analysis and Guidance: Sichuan’s Class II Medical Device Initial Registration Product Directory

Sichuan Provincial Drug Administration has released the initial registration product directory for Class II medical devices for March 2025. This initiative aims to enhance transparency, ensure compliance, and support the development of the medical device industry.

Key Policy Highlights

  1. Registration Information Disclosure
    • Purpose: To provide the public with accurate and timely information on newly registered Class II medical devices.
    • Details: The directory includes detailed registration information for multiple medical device companies, such as Chengdu Kanghuijing Technology Co., Ltd. and Wangcheng Medical Technology (Chengdu) Co., Ltd.
  2. Regulatory Compliance
    • Standards: Ensuring all registered medical devices comply with national standards and regulations.
    • Transparency: Making registration information publicly available to enhance trust and facilitate industry supervision.
  3. Industry Support
    • Development: Supporting the innovation and development of the medical device industry through clear and efficient regulatory processes.
    • Efficiency: Streamlining the registration process to reduce administrative burdens and promote industry growth.

Policy Orientation and Industry Implications
The initial registration product directory policy reflects Sichuan’s strategic focus on:

  • Transparency: Ensuring public access to accurate and timely registration information.
  • Compliance: Strengthening regulatory frameworks to ensure product safety and quality.
  • Industry Growth: Supporting the innovation and sustainable development of the medical device sector.

Conclusion
Sichuan’s approach to Class II medical device initial registration sets a benchmark for regional medical device regulation, emphasizing transparency, compliance, and industry support. Medical device enterprises should align with these guidelines to ensure smooth operations and build public trust.-China Health Reform Pulse

Policy Source: http://yjj.sc.gov.cn/scyjj/c103181/2025/4/1/53dabb2afc2547e4bbc9a1ed78f3ce27.shtml

Policy Analysis and Guidance: Yunnan’s Announcement on Credit Rating Notifications for Dishonest Enterprises

Yunnan Provincial Government Procurement and Tendering Center has issued an announcement regarding credit rating notifications for dishonest enterprises involved in pharmaceutical commercial bribery. This initiative aims to strengthen the regulation of the pharmaceutical industry, combat commercial bribery, and maintain market order and fair competition.

Key Policy Highlights

  1. Credit Evaluation
    • Objective: To evaluate the credit of enterprises involved in pharmaceutical commercial bribery cases and issue corresponding ratings.
    • Basis: The evaluation is conducted in accordance with the “Operational Norms for Pharmaceutical Price and Tendering Credit Evaluation (2020 Edition)”.
  2. Notification and Collection
    • Process: Enterprises listed in the announcement must collect their credit rating notifications by April 9, 2025.
    • Location: Notifications can be collected at Room 402, Transaction Building, No. 269 Kefa Road, Kunming High-Tech Zone.
  3. Consequences of Non-Compliance
    • Deadline: Failure to collect the notification by the specified date may result in adverse consequences for the enterprises involved.

Policy Orientation and Industry Implications
The credit rating policy reflects Yunnan’s strategic focus on:

  • Market Regulation: Combating commercial bribery to maintain a fair and orderly market environment.
  • Transparency: Enhancing transparency in the pharmaceutical industry through credit evaluations.
  • Compliance: Encouraging enterprises to adhere to legal and ethical standards in their operations.

Conclusion
Yunnan’s approach to credit rating notifications for dishonest enterprises sets a benchmark for regional pharmaceutical industry regulation, emphasizing transparency, compliance, and market integrity. Enterprises in the sector should align with these guidelines to maintain compliance and contribute to a fair market environment.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25193&CatalogId=3

Policy Analysis and Guidance: Guangdong Province’s Volume-Based Drug Procurement Initiative

Guangdong Province’s Drug Exchange Center has issued a notice outlining the implementation details of the centralized volume-based procurement initiative for medications such as Apixaban tablets. This policy, effective from April 1, 2025, to December 31, 2025, aims to streamline drug procurement processes, enhance supply chain stability, and ensure quality assurance across healthcare institutions.

Key Policy Measures

  1. Tripartite Contract Signing
    • Process: Medical institutions must use CA certificates to log into Guangdong’s tender and procurement subsystem to initiate tripartite contracts. Detailed operational guidance is available on the official website.
    • Timeline: Contracts must be completed promptly after initiation by medical institutions, with drug manufacturers and distributors required to log in and finalize agreements without delay.
  2. Quality and Supply Responsibility
    • Accountability: Drug manufacturers are designated as the primary responsible parties for ensuring the quality and timely delivery of medications. They must guarantee coverage of all participating healthcare institutions across the province.
    • Compliance: Selected manufacturers must adhere to agreed-upon procurement volumes and ensure uninterrupted supply chains.
  3. Procurement Volume Negotiation
    • Flexibility: For designated social healthcare institutions, procurement volumes will be determined through negotiations between supply and demand parties, allowing for tailored agreements.

Policy Orientation and Industry Implications
This initiative reflects Guangdong’s strategic focus on:

  • Cost Efficiency: Reducing drug prices through centralized procurement while maintaining quality standards.
  • Supply Chain Integrity: Ensuring uninterrupted medication supply to healthcare facilities across the province.
  • Transparency: Promoting clear contractual agreements and accountability mechanisms.

Conclusion
Guangdong’s volume-based procurement framework sets a benchmark for regional drug management, emphasizing efficiency, quality, and accessibility. Stakeholders, including manufacturers, distributors, and healthcare providers, should align their operations with these guidelines to optimize compliance and patient outcomes.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1906642648857317376